Ernexa Therapeutics CEO Sanjeev Luther shares how clinical research has revealed why certain cancers resist treatment and how emerging cell therapies may help break through those defenses.
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- Active Versus Passive Shipping Solutions For Clinical Shipments
- January 2026 — CDMO Opportunities And Threats Report
- Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones
- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
- Why Clinical Supply Risk Starts With Demand Signals
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Mammalian Display Method For The Development Of Enhanced Affinity TCR-Based Biologics
Discover how mammalian display enhances T cell receptor-based cancer therapies. This method improves antigen affinity and reduces immunogenicity for more effective treatments.
-
Automated DNA Size Selection For Flexible NGS Workflow Integration
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Advances In Flow-Through Technology To Enhance mAb Polishing
Optimize your monoclonal antibody purification with cutting-edge flow-through chromatography. Learn how POROS resins enhance polishing efficiency, improve aggregate removal, and streamline bioprocessing.
-
Epigenetics Application Guide: RNA Modifications
Learn about the rapidly evolving field of RNA modifications, including innovative techniques like miCLIP and RIP for mapping chemical modifications and understanding RNA’s role in cellular processes.
-
The State Of Digital Maturity In Pharma And Medtech Manufacturing
Explore results from a study aiming to understand why numerous companies continue to rely on manual, paper-based systems, and gain insight into how your competitors are gaining a competitive advantage.
-
CAR Expression Detection Using Fluorescent Labeled Proteins, Flow Cytometry
Learn how site-specific fluorescent labeling addresses key challenges in flow cytometry-based evaluations by enhancing assay sensitivity, reducing variability, and ensuring reliable results.
-
Performance Comparison Of The Vericheck ddPCR™ Empty-Full Capsid Kit And Analytical Ultracentrifugation (AUC)
Discover how Droplet Digital PCR (ddPCR) offers a precise analysis of AAV capsid content, outperforming analytical ultracentrifugation (AUC) in distinguishing therapeutic genomes from contaminants.
-
Use Cation Exchange Chromatography For High Yields In Vaccine Production
Learn how to achieve high yields in vaccine production by using Cation Exchange Chromatography for purifying SARS-CoV-2 spike proteins. This method provides high purity and minimizes protein aggregates.
-
Improved T Cell Expansion Using Closed, Automated Stirred-Tank Bioreactors
A shift from traditional rocking motion systems to stirred-tank bioreactors can enhance T cell expansion, offering greater scalability and more intimate process control.
-
Best Practices For Regulatory Excellence In Clinical Research
Observe how GCLP can integrate ethical and technical standards to ensure reliable, compliant clinical trial data and optimize laboratory operations across sponsors, CROs, and partners.
NEWSLETTER ARCHIVE
- 02.20.26 -- Deciding When Research Grade Raw Materials Are Sufficient
- 02.19.26 -- Advancing Your Cell and Gene Therapy Journey
- 02.19.26 -- Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones
- 02.18.26 -- Specialized Fill/Finish For Advanced Therapies
- 02.18.26 -- Cold-Chain Packaging Strategies For Scaling Gene Therapies
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections